iTeos Therapeutics, Inc. (NASDAQ:ITOS) Holdings Cut by Vestal Point Capital LP

Vestal Point Capital LP lowered its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 12.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 900,000 shares of the company's stock after selling 125,000 shares during the quarter. Vestal Point Capital LP owned about 2.46% of iTeos Therapeutics worth $6,912,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in ITOS. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of iTeos Therapeutics in the fourth quarter valued at approximately $42,000. Virtus ETF Advisers LLC boosted its holdings in shares of iTeos Therapeutics by 58.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after acquiring an additional 3,293 shares in the last quarter. Forefront Analytics LLC bought a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $85,000. Graham Capital Management L.P. bought a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $85,000. Finally, Clear Harbor Asset Management LLC bought a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $96,000. Institutional investors and hedge funds own 97.16% of the company's stock.

Insider Activity at iTeos Therapeutics

In other iTeos Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the sale, the insider now owns 2,108,594 shares in the company, valued at $16,995,267.64. This represents a 23.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the sale, the insider now owns 3,452,797 shares of the company's stock, valued at approximately $27,829,543.82. The trade was a 23.01% decrease in their position. The disclosure for this sale can be found here. 12.50% of the stock is owned by insiders.

iTeos Therapeutics Stock Performance

Shares of NASDAQ:ITOS traded down $0.13 during mid-day trading on Friday, hitting $8.56. The stock had a trading volume of 611,821 shares, compared to its average volume of 569,146. The company has a market cap of $327.63 million, a PE ratio of -2.72 and a beta of 1.39. iTeos Therapeutics, Inc. has a 12-month low of $4.80 and a 12-month high of $18.13. The company's 50 day moving average is $6.72 and its 200-day moving average is $7.40.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.14. On average, equities research analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wedbush restated an "outperform" rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Raymond James set a $12.00 target price on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Leerink Partners restated a "market perform" rating and set a $9.00 target price (down from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Piper Sandler restated an "overweight" rating and set a $12.00 target price (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Wells Fargo & Company restated an "overweight" rating and set a $13.00 target price (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $17.86.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.